AVNS

Avanos Medical, Inc. AVNS reported first-quarter 2026 adjusted earnings per share (EPS) from continuing operations of 22 cents, down 15.4% year over year. The bottom line missed the Zacks Consensus Estimate of 23 cents. GAAP EPS from continuing operations in the quarter under review was 11 cents compared with the year-ago period’s EPS of 14 cents. Revenues totaled $182.2 million in the reported quarter, up 8.8% year over year. The metric beat the Zacks Consensus Estimate by 7.6%. The top line gained from higher volume across its Specialty Nutrition Systems (SNS) segments. Shares of the company gained nearly 0.1% during after-market trading following the first-quarter results on Monday. The company’s shares have jumped 120.1% in the year-to-date period against the industry’s decline of 15.7%. The broader S&P 500 Index has increased 6.8% in the same time frame. Image Source: Zacks Investment Research Avanos generates revenues from three segments: SNS, PM&R, and Corporate and Other. The SNS segment’s revenues in the first quarter of 2026 totaled $124 million, up 22.7% year over year. This figure beat our first-quarter projection of $107 million. The segment recorded 19% volume growth, driven by continued strong demand across both our enteral feeding and neonate solutions. The Enteral feeding unit’s revenues totaled $84.6 million for the first quarter of 2026 (up 13.6% year over year), while the Neonate solutions unit’s revenues amounted to $39.4 million (up 48.1% year over year). The PM&R segment’s revenues totaled $56.3 million, up 0.2% year over year. However, the figure missed our projection of $62 million. The PM&R segment’s volume growth in Radio Frequency Ablation (RFA) was partially offset by reduced volume in surgical pain and recovery product lines. Net sales of RFA products grew 8.8% year over year to $34.5 million, reflecting momentum in RFA generator sales. Net sales in the surgical pain and recovery unit declined 11% year over year to $21.8 million. The Corporate and Other segment’s revenues totaled $1.9 million, down 81.4% year over year. In the quarter under review, Avanos’ adjusted gross profit increased 2.4% year over year to $97.3 million. The adjusted gross margin contracted 330 basis points (bps) to 53.4%. We had projected a gross margin of 54.2% for the first quarter. Selling and general expenses increased 2.6% year over year to $77.7 milli...

ALPHARETTA, Ga. (AP) — ALPHARETTA, Ga. (AP) — Avanos Medical, Inc. (AVNS) on Tuesday reported first-quarter earnings of $5.1 million. On a per-share basis, the Alpharetta, Georgia-based company said it had profit of 11 cents. Earnings, adjusted for one-time gains and costs, came to 22 cents per share. The medical technology company posted revenue of $182.2 million in the period. Avanos Medical shares have more than doubled since the beginning of the year. The stock has more than doubled in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AVNS at https://www.zacks.com/ap/AVNS

Delivered double-digit organic growth led by Specialty Nutrition Systems segment Generated $0.11 of diluted earnings per share and $0.22 of adjusted diluted earnings per share On April 14, 2026, announced the execution of a definitive agreement to be acquired by certain affiliates of American Industrial Partners ("AIP") in an all-cash offer at an enterprise value of $1.272 billion ALPHARETTA, Ga., May 5, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported first quarter 2026 financial results. "Building off our strong 2025 results, we delivered solid first quarter performance led by double-digit organic revenue growth in our Specialty Nutrition Systems segment," said David Pacitti, Avanos' chief executive officer. Pacitti continued, "Our overall execution this quarter was positive, and I'm very pleased with the steady progress we're making against each of our strategic imperatives." First Quarter 2026 Highlights Total net sales were $182.2 million, an 8.8% increase from the comparable prior year period. Net income was $5.1 million, compared to $6.6 million a year ago. Adjusted net income was $10.6 million, compared to $12.0 million a year ago. Diluted earnings per share was $0.11, compared to $0.14 a year ago. Adjusted diluted earnings per share was $0.22, compared to $0.26 a year ago. Adjusted EBITDA was $21.8 million, compared to $21.6 million a year ago. Specialty Nutrition Systems Segment The Specialty Nutrition Systems ("SNS") segment delivered above-market results in the first quarter of 2026, achieving net sales of $124.0 million, an increase of $22.9 million compared to the prior year period. Operating income in the SNS segment for the three months ended March 31, 2026 was $23.1 million, or 18.6% of SNS net sales, an increase of $2.0 million compared to the prior year period. Pain Management & Recovery Segment Pain Management and Recovery ("PM&R") segment net sales for the first quarter of 2026 were $56.3 million. Overall PM&R net sales growth was relatively flat compared to the prior year period. Operating loss in the PM&R segment for the first quarter of 2026 was $1.8 million compared to operating income of $0.2 million last year. Cash Flow and Balance Sheet Cash used in operations for the three months ended March 31, 2026 was $12.3 million, compared to cash flow from operations of $25.7 million a year ago. For the three months end...

Avanos Medical (AVNS) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -4.35%. A quarter ago, it was expected that this medical technology company would post earnings of $0.24 per share when it actually produced earnings of $0.29, delivering a surprise of +20.83%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Avanos Medical, which belongs to the Zacks Medical - Instruments industry, posted revenues of $182.2 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 7.61%. This compares to year-ago revenues of $167.5 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Avanos Medical shares have added about 119.6% since the beginning of the year versus the S&P 500's gain of 5.2%. While Avanos Medical has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Avanos Medical was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of toda...

US equity futures were trending higher on Tuesday amid media reports that the US and Iran may revive

It has been about a month since the last earnings report for NeuroPace, Inc. (NPCE). Shares have added about 0.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is NeuroPace due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts. NeuroPace reported a loss per share of 8 cents in the fourth quarter, compared to 18 cents in the year-ago period. The company beats Zacks Consensus Estimate of a loss of 14 cents per share by 41.48%. Revenue in the fourth quarter 2025 reached $26.6 million, up 24% year over year, reflecting strong RNS System sales of $22.4 million (up 26%) alongside $890,000 in service revenue and $3 million from DIXI Medical wind-down. The revenues also beat the Zacks Consensus Estimate by 2.47% Operating expenses totaled $22.3 million, up 13% year over year (Sales & Marketing $10.9 million; R&D $ million; G&A $4.4 million). Importantly, adjusted EBITDA turned positive at $0.9M, marking a second consecutive quarter of positive adjusted EBITDA. Q4 marked all-time highs in prescribers, implanters, and patient funnel, with contributions from community pathways expanding beyond Level 4 centers. Gross margin expanded to 77.4%, up 200 bps year over year, with RNS gross margin at 80.5%, up 40 bps, supported by mix shift, manufacturing efficiencies, and pricing conversion. NeuroPace ended fourth quarter of 2025 with $61.1M in cash and short-term investments, compared to $60 million in the third quarter. The fourth quarter generated positive operating cash flow of $500 ,000 and positive free cash flow of $400,000, demonstrating improving cash generation. Long-term debt stood at $58.9 million. For 2026, management reiterated total revenue guidance of $98million-$100 million on a continuing-operations basis, with RNS growth of 20%-22%, excluding any IGE contribution and DIXI. Adjusted gross margin is expected at 81.5%-82.5%, supported by ongoing pricing discipline and manufacturing efficiencies. Adjusted operating expenses are guided to $90 million - $92million, with adjusted EBITDA expected to be a loss of approximately $9 million-$1 milliom due to front-loaded first-half spending and typical procedural seasonality. First quart...

Avanos Medical, Inc. AVNS reported fourth-quarter 2025 adjusted earnings per share (EPS) from continuing operations of 29 cents, down 32.6% year over year. However, the bottom line beat the Zacks Consensus Estimate of 24 cents by 20.8%. GAAP loss per share from continuing operations in the quarter under review was 3 cents compared with the year-ago period’s loss per share of $8.63. Revenues totaled $180.9 million in the reported quarter, up 0.7% year over year. The metric beat the Zacks Consensus Estimate by 2.7%. The top line gained fromhigher volume across both its Specialty Nutrition Systems ("SNS") and Pain Management and Recovery ("PM&R") segments. However, shares of the company lost nearly 10% in yesterday’s trading. The company ’s shares have plunged 37.9% in the year-to-date period compared with the industry’s decline of 8.9%. The broader S&P 500 Index has increased 7.3% in the same time frame. Avanos generates revenues from three segments — SNS, PM&R and Corporate and Other. PM&R segment’s revenues in the fourth quarter of 2025 totaled $61.6 million, up 1.3% year over year. This figure compares to our projection of $57.7 million. The PM&R segment’s volume growth in Radio Frequency Ablation ("RFA") was partially offset by reduced volume in our surgical pain and recovery product lines. Net sales of RFA products grew 8.2% year over year to $36.9million, reflecting momentum in RFA generator sales. Net sales in the surgical pain and recovery unit declined 7.5% year over year to $24.7million, primarily due to lower volume in the Game Ready product line. SNS segment’s revenues totaled $115.1 million, up 8.7% year over year. This figure compares to our fourth-quarter projection of $98.1 million. The segment recorded 7.9% volume growth, driven by continued strong demand across both Avanos’ enteral feeding and neonate solutions categories, especially long-term feeding products and US CORTRAK standard of care offerings. Enteral feeding unit’s revenues totaled $83 million for the fourth quarter of 2025 (up 10.7% year over year), while Neonate solutions unit’s revenues amounted to $32.1 million (up 3.9% year over year). Corporate and Other segment’s revenues totaled $4.2 million, down 67.4% year over year. The segment includes the Hyaluronic Acid (HA) injections and intravenous infusion product lines. In July, AVNS announced the divestiture of its HA product lin...

Avanos topped revised 2025 guidance with full-year net sales of $701 million and adjusted diluted EPS of $0.94, and for 2026 it guides sales of $700–720 million and adjusted diluted EPS of $0.90–1.10. The Specialty Nutrition Systems business was a standout—growing over 8% organically in 2025 with short-term enteral posting double-digit global growth, while Pain Management’s RFA business also delivered double-digit growth; the Nexus neonatal acquisition contributed $5 million in 2025 and is expected to be a double-digit grower in 2026. Tariffs remain a major headwind: management assumes about a $30 million tariff P&L impact in 2026 (a $12 million increase from 2025), with roughly two-thirds China-related, and plans to exit China syringe sourcing by June, shifting production to Mexico and Cambodia while using USMCA/Nairobi exemptions where possible. Interested in Avanos Medical, Inc.? Here are five stocks we like better. Avanos Medical (NYSE:AVNS) management said it delivered “solid” fourth-quarter and full-year 2025 results, pointing to progress on its strategic priorities and continued strength in its Specialty Nutrition Systems (SNS) business, while also outlining plans to mitigate tariff impacts and improve operating efficiency. Chief Executive Officer Dave Pacitti said Avanos generated full-year net sales of $701 million, exceeding the range the company revised after the third quarter. He added that Avanos finished at the high end of its revised earnings guidance range, delivering $0.94 in adjusted diluted earnings per share for the year. → Hinge Health’s AI Moat Might Be Its Patient Movement Data For the fourth quarter, the company reported net sales of approximately $181 million. Pacitti said organic sales for the company’s strategic segments rose 3.4% year over year when adjusted for foreign exchange and the effect of the company’s decision to exit certain revenue streams that did not meet its return criteria. In the quarter, Avanos reported $0.29 in adjusted diluted EPS and $28 million of adjusted EBITDA. Adjusted gross margin was 53.4% and adjusted SG&A was 39.1% of revenue. For the full year, adjusted EBITDA was $87 million, adjusted gross margin was 54.6%, and adjusted SG&A was 42% of revenue. → Gold and Silver Pulled Back—Here’s Why the Bull Case Is Intact Pacitti said the SNS portfolio delivered “strong above market” performance in 2025, growing...

This article first appeared on GuruFocus. Full-Year Net Sales: $701 million. Adjusted Diluted Earnings Per Share (Full Year): $0.94. Fourth-Quarter Net Sales: Approximately $181 million. Adjusted Diluted Earnings Per Share (Q4): $0.29. Adjusted EBITDA (Q4): $28 million. Adjusted Gross Margin (Q4): 53.4%. Adjusted SG&A as Percentage of Revenue (Q4): 39.1%. Adjusted Organic Sales Growth (Full Year): 6%. Adjusted EBITDA (Full Year): $87 million. Adjusted Gross Margin (Full Year): 54.6%. Adjusted SG&A as Percentage of Revenue (Full Year): 42%. Specialty Nutrition Systems Organic Growth (Full Year): Over 8%. Pain Management and Recovery Organic Sales Growth (Full Year): 2.3%. Operating Profit (Specialty Nutrition Systems): 19%. Operating Profit (Pain Management and Recovery): 4%. Cash on Hand (End of Year): $90 million. Debt Outstanding (End of Year): $100 million. Free Cash Flow (Q4): $21 million. Free Cash Flow (Full Year): $43 million. 2026 Net Sales Guidance: $700 million to $720 million. 2026 Adjusted Diluted EPS Guidance: $0.90 to $1.10. 2026 Capital Expenditures Guidance: $25 million. 2026 Effective Tax Rate Guidance: Approximately 29%. Warning! GuruFocus has detected 6 Warning Signs with AVNS. Is AVNS fairly valued? Test your thesis with our free DCF calculator. Release Date: February 24, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Avanos Medical Inc (NYSE:AVNS) delivered full-year net sales of $701 million, exceeding revised expectations. The Specialty Nutrition Systems portfolio grew over 8% organically, reaffirming market-leading positions. The radiofrequency ablation business posted double-digit organic growth, contributing to overall success. Successful execution of tariff mitigation strategies is expected to benefit financial performance in 2026. The Nexus Medical acquisition has been integrated successfully, contributing positively to growth. Tariffs significantly impacted profitability in 2025, with ongoing challenges expected in 2026. The surgical pain business experienced a year-over-year decline due to delayed NOPAIN Act implementation. The Game Ready portfolio posted similar revenue levels year-over-year, indicating stagnation. Operating profit for the Specialty Nutrition Systems segment decreased by 100 basis points due to tariffs. The hyaluronic acid and IV therapy product lines d...

Management is reshaping the company into a focused medical technology organization by divesting low-growth, low-margin assets like hyaluronic acid and IV therapy. Specialty Nutrition Systems (SNS) outperformed market trends with 8% organic growth, driven by the U.S. CORTRAK standard of care and international go-direct transitions. The Pain Management portfolio saw double-digit growth in radiofrequency ablation (RFA) capital sales, which management expects will drive future procedural volumes. Surgical pain performance was hindered by slower-than-anticipated hospital implementation of the NOPAIN Act reimbursement, despite Avanos holding several approved devices. Profitability in 2025 was significantly obscured by tariff impacts, prompting a comprehensive internal cost containment and pricing strategy to protect margins. The acquisition of Nexus Medical is being leveraged through existing NICU sales channels, exceeding initial integration expectations. Management expects to be fully exited from China manufacturing for the syringe portfolio by June 2026, shifting production to Mexico and Cambodia. The 2026 guidance assumes a $30 million tariff impact, a $12 million increase over 2025, primarily driven by neonatal products sourced from China prior to the exit. Gross margin improvement is expected to pause in the first half of 2026 due to tariff timing, with favorable momentum projected for the second half and into 2027. Strategic segment revenue is projected to grow mid-single digits organically, supported by double-digit growth expectations for the Nexus product line. Capital expenditures are budgeted at $25 million to support the accelerated China exit plan and the transition of production to the Tijuana, Mexico facility. The company is monitoring recent Supreme Court rulings on tariffs for potential financial outlook adjustments once administrative clarity is reached. A strategic exit from the IV therapy business is scheduled for completion in the first quarter of 2026, effectively removing it from the core portfolio. The Nairobi protocol and USMCA provide critical tariff exemptions for 60% to 70% of products manufactured in Mexico, serving as a key pillar of the mitigation strategy. R&D strategy has shifted toward a hybrid model of internal projects and outsourced development to maintain innovation without increasing R&D as a percentage of sales. Our analyst...

Avanos Medical (AVNS) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +20.83%. A quarter ago, it was expected that this medical technology company would post earnings of $0.16 per share when it actually produced earnings of $0.22, delivering a surprise of +37.5%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Avanos Medical, which belongs to the Zacks Medical - Instruments industry, posted revenues of $180.9 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.71%. This compares to year-ago revenues of $179.6 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Avanos Medical shares have added about 35.6% since the beginning of the year versus the S&P 500's decline of 0.1%. While Avanos Medical has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Avanos Medical was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete lis...

Exceeded full-year revenue and achieved the top end of full-year earnings-per-share guidance Delivered full-year organic growth of 6% in strategic segments Expanded transformation initiatives expected to deliver $15 to $20 million of incremental annualized savings by the end of 2026 ALPHARETTA, Ga., Feb. 24, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2025 results. "I'm very pleased with our fourth quarter and full-year results, which demonstrate meaningful progress on our strategic priorities," said David Pacitti, Avanos' chief executive officer. Pacitti continued, "Our organic growth remains healthy and positions us well for 2026. Our tariff mitigation efforts are on track, and we're beginning to see the impact of our cost management initiatives. I'm proud of our team's focus and commitment." Fourth Quarter 2025 Highlights Total fourth quarter net sales were $180.9 million, a 0.7% increase from the prior year period. Operating income in the quarter was $2.5 million compared to operating loss of $418.5 million in the prior year period. On an adjusted basis, operating income was $22.6 million compared to $23.9 million a year ago. Net loss for the quarter was $1.3 million, compared to net loss of $397.0 million in the prior year period. On an adjusted basis, fourth quarter net income was $13.4 million compared to $20.0 million in the prior year. Fourth quarter diluted loss per share was $0.03 compared to diluted loss per share of $8.63 a year ago. On an adjusted basis, fourth quarter diluted earnings per share was $0.29 compared to $0.43 in the prior year. Adjusted EBITDA for the quarter was $28.0 million compared to $28.6 million in the prior year period. Fourth quarter free cash flow was $21.3 million compared to $53.1 million in the fourth quarter of last year. Specialty Nutrition Systems Segment The Specialty Nutrition Systems ("SNS") segment delivered above-market results in the fourth quarter of 2025, achieving net sales of $115.1 million, an increase of 8.7% compared to the prior year period. Operating income in the SNS segment for the fourth quarter of 2025 was $20.5 million, or 17.8% of SNS net sales, a decrease of $4.5 million. Pain Management and Recovery Segment Pain Management and Recovery ("PM&R") segment net sales for the fourth quarter of 2025 was $61.6 million, an increase of 1.3% compare...